Completed PHASE3 INTERVENTIONAL 2-arm NCT01028170

Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure (REaCH)

Assessing the Renal Consequences and Functional Efficacy of Low Dose Hypertonic Saline Solution and Furosemide for the Treatment of Congestive Heart Failure in a Randomized, Double Blind, Prospective Study

Sponsor: Aspirus Heart and Vascular Institute-Research and Education

Conditions Congestive Heart Failure Renal Insufficiency

Interventions furosemide furosemide and hypertonic saline solution

Updated 6 times since 2017 Last updated: Feb 8, 2012 Started: Nov 30, 2009 Primary completion: Jul 31, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Congestive Heart Failure and Renal Insufficiency, this trial is completed. The trial is conducted by Aspirus Heart and Vascular Institute-Research and Education and has accumulated 6 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aspirus Heart and Vascular Institute-Research and Education
Aspirus Wausau Hospital

Data source: Aspirus Heart and Vascular Institute-Research and Education

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wausau, United States